Holen Sie sich die Stockscreener-App
57.54
2.90%
1.62
Vorhandelsmarkt:
57.84
0.30
+0.52%
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme to Report Second Quarter 2025 Financial and Operating Results - cnhinews.com
What analysts say about Halozyme Therapeutics Inc. stockConsistently exceptional gains - jammulinksnews.com
What drives Halozyme Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - Yahoo Finance
Halozyme Therapeutics Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com
Halozyme Stock Maintains Hold Rating Amid CMS Pricing Uncertainty and Regulatory Concerns. - AInvest
Is Halozyme Therapeutics Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com
Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $60.00 - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
How Halozyme Therapeutics Inc. stock performs during market volatilityFree AI-Powered Stock Predictions - beatles.ru
Halozyme Therapeutics: A 20% CAGR Growth Story Powered by ENHANZE, Litigation Upside, and Undervalued M&A Potential - AInvest
Halozyme Therapeutics' strategic adoption - MarketScreener
Halozyme Therapeutics (HALO): Navigating Regulatory Crosscurrents to Seize Long-Term Value - AInvest
Halozyme Therapeutics Downgraded Amid Concerns Over Long-Term Value. - AInvest
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) (HALO) - Seeking Alpha
Halozyme Therapeutics: CEO Stock Sales vs. Robust Pipeline and Financial Momentum - AInvest
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises By Investing.com - Investing.com South Africa
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises - Investing.com Nigeria
Halozyme stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com Canada
Goldman Sachs Resumes Coverage of Halozyme (HALO) with Neutral R - GuruFocus
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga
Halozyme Therapeutics Added to Russell 1000® Index - Eastern Progress
Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday - MSN
Halozyme Therapeutics (HALO): A Momentum Stock to Consider - AInvest
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics Added to Russell 1000® Index | HALO Stock News - GuruFocus
Halozyme Therapeutics: A Catalyst-Fueled Ascension to the Russell 1000 - AInvest
Halozyme therapeutics added to Russell 1000 index By Investing.com - Investing.com South Africa
Halozyme therapeutics added to Russell 1000 index - Investing.com
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve
Breakthrough for CIDP Patients: EU Green Lights First Novel Treatment in 3 DecadesHalozyme Partnership Delivers - Stock Titan
Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media
Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):